Sutro Biopharma: Difference between revisions
added internal links to clarify terms |
No edit summary Tags: Visual edit Mobile edit Mobile web edit Advanced mobile edit |
||
(19 intermediate revisions by 16 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Biotechnology company based in South San Francisco, California}} |
|||
{{More citations needed|date=April 2019}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| founded = {{start date and age|2003}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
}} |
|||
⚫ | '''Sutro Biopharma, Inc.''' is a [[Public company|publicly traded]] [[biotechnology]] company headquartered in [[South San Francisco]], California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary [[cell-free protein synthesis]] platform, Sutro is working on oncology therapeutics using protein engineering and [[rational design]]. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO {{As of|2024|lc=y}}, joined Sutro in January 2009.<ref>{{cite press release| title=William J. Newell Named Chief Executive Officer of Sutro Biopharma – Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer – Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco | publisher=Sutro Biopharma, Inc. | date=12 January 2009 | url=https://www.sutrobio.com/william-j-newell-named-chief-executive-officer-of-sutro-biopharma-former-ceo-daniel-s-gold-ph-d-becomes-president-and-chief-operating-officer-company-notes-name-change-from-fundamental-applied/}}</ref> |
||
{{refimprove}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed [[Antibody-drug conjugate|antibody drug conjugates]], or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in [[multiple myeloma]] and [[Non-Hodgkin lymphoma|non-Hodgkin's lymphoma]], and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting [[folate receptor alpha]], a cell-surface protein highly expressed in gynecological cancers. |
||
⚫ | '''Sutro Biopharma, Inc.''' is a |
||
⚫ | |||
The company has raised over $275m from venture investors, collaborators and the public markets.{{fact}} |
|||
⚫ | |||
⚫ | |||
==Technology== |
==Technology== |
||
Sutro's Xpress CF Platform<ref>{{cite news |title= About Sutro's technology| |
Sutro's Xpress CF Platform<ref>{{cite news |title= About Sutro's technology|url=http://www.sutrobio.com/technology/}}</ref> is based on [[Stanford University|Stanford]] Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology.<ref name=":0">{{cite journal | vauthors = Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, Gold DS, Heinsohn HG, Murray CJ | title = Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines | journal = Biotechnology and Bioengineering | volume = 108 | issue = 7 | pages = 1570–8 | date = July 2011 | pmid = 21337337 | pmc = 3128707 | doi = 10.1002/bit.23103 }}</ref> XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins.<ref name=":0" /> The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs).<ref>{{cite news |title=Sutro's ADC technology|url=http://www.sutrobio.com/technology/}}</ref> Once identified, production of protein drug candidates can be scaled in Sutro's [[Current good manufacturing practice|cGMP]] manufacturing facility located in [[San Carlos, California|San Carlos, CA]]. |
||
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over [[US$]]170 million in capital.<ref>{{Cite web|url=https://endpts.com/tilting-at-vaccines-giants-sutrovax-fuels-up-on-a-170m-plus-quest-to-vault-past-the-worlds-best-selling-vaccine/|title=Tilting at vaccines giants, SutroVax fuels up on a $170M-plus quest to vault past the world's best-selling vaccine|website=Endpoints News|language=en-US|access-date=2019-04-25}}</ref> |
|||
==Collaborations== |
==Collaborations== |
||
In July 2018, Sutro signed a collaboration and licensing agreement with [[Merck & Co.|Merck]] to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 |
In July 2018, Sutro signed a collaboration and licensing agreement with [[Merck & Co.|Merck]] to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and [[Celgene]] announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting [[B-cell maturation antigen|B-Cell maturation antigen]] (BCMA). |
||
== Awards == |
== Awards == |
||
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce |
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014.<ref>{{Cite web|url=https://www.fiercebiotech.com/special-report/fiercebiotech-s-2014-fierce-15|title=FierceBiotech's 2014 Fierce 15|website=FierceBiotech|language=en|access-date=2019-04-23}}</ref> In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.<ref>{{Cite news|url=https://califesciences.org/distinguished-life-sciences-leaders-to-be-honored-at-clsas-2015-pantheon-dina-awards-ceremony/|title=Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony - California Life Sciences Association|date=2015-11-09|work=California Life Sciences Association|access-date=2018-11-28|language=en-US}}</ref> |
||
== References == |
== References == |
||
{{Reflist}} |
{{Reflist}} |
||
{{Authority control}} |
|||
[[Category:Biopharmaceutical companies]] |
[[Category:Biopharmaceutical companies]] |
||
[[Category:Biotechnology companies of the United States]] |
[[Category:Biotechnology companies of the United States]] |
||
[[Category:South San Francisco, California]] |
[[Category:Companies based in South San Francisco, California]] |
||
[[Category:Pharmaceutical companies established in 2003]] |
[[Category:Pharmaceutical companies established in 2003]] |
||
[[Category:Companies listed on the Nasdaq]] |
Latest revision as of 14:53, 9 July 2024
This article needs additional citations for verification. (April 2019) |
Company type | Public |
---|---|
Nasdaq: STRO Russell 2000 Index component | |
Industrie | Biotechnology |
Gegründet | 2003 |
Hauptsitz | South San Francisco |
Number of employees | 290 |
Website | sutrobio |
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024[update], joined Sutro in January 2009.[1]
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024[update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Technologie
[edit]Sutro's Xpress CF Platform[2] is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology.[3] XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins.[3] The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs).[4] Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.[5]
Collaborations
[edit]In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
[edit]The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014.[6] In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.[7]
References
[edit]- ^ "William J. Newell Named Chief Executive Officer of Sutro Biopharma – Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer – Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco" (Press release). Sutro Biopharma, Inc. 12 January 2009.
- ^ "About Sutro's technology".
- ^ a b Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, Gold DS, Heinsohn HG, Murray CJ (July 2011). "Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines". Biotechnology and Bioengineering. 108 (7): 1570–8. doi:10.1002/bit.23103. PMC 3128707. PMID 21337337.
- ^ "Sutro's ADC technology".
- ^ "Tilting at vaccines giants, SutroVax fuels up on a $170M-plus quest to vault past the world's best-selling vaccine". Endpoints News. Retrieved 2019-04-25.
- ^ "FierceBiotech's 2014 Fierce 15". FierceBiotech. Retrieved 2019-04-23.
- ^ "Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony - California Life Sciences Association". California Life Sciences Association. 2015-11-09. Retrieved 2018-11-28.